Erythropoietin and the anemia of cancer

Acta Clinica Belgica

Volumn 51, Issue 1, 1996, Pages 36-52

  Beguin, Y ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DAUNORUBICIN; ERYTHROPOIETIN; IFOSFAMIDE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER; CANCER CHEMOTHERAPY; ERYTHROCYTE CONCENTRATE; FLUSHING; HUMAN; HYPOTENSION; MYALGIA; NAUSEA; PATHOGENESIS; PRURITUS; RASH; REVIEW; SIDE EFFECT;

EID: 0029880582     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1996.11718483     Document Type: Review

References (104)

1. Spivak JL. Cancer-related anemia: Its causes and characteristics. Semin Oncol. 1994; 21 (Suppl.3): 3-8.
2. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992; 80: 1639-47.
3. Lee GR. The anemia of chronic disease. Semin Hematol. 1983; 20: 61-80.
4. Sears D. Anemia of chronic disease. Med Clin North Am. 1992; 76: 567-79.
5. Roeser HP. Iron metabolism in inflammation and malignant disease. In: Jacobs A, Worwood M, eds. Iron in biochemistry and medicine II. London: Academic Press, 1980: 605-40.
6. Letendre ED. Iron metabolism during infection and neoplasia. Cancer Metastasis Rev. 1987; 6: 41-53.
7. Cartwright GE. The anemia of chronic disorders. Semin Hematol. 1966, 3: 351-75.
8. Konijn AM. Iron metabolism in inflammation. Clin Haematol. 1994; 7: 829-49.
9. Cazzola M, Bergamaschi G, Dezza L, Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood. 1990; 75: 1903-19.
10. Means RT Jr., Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest. 1993; 91: 416-9.
11. Wang CQ, Udupa KB, Lipschitz DA. The role of macrophages in the regulation of erythroid colony growth in vitro. Blood. 1992; 80: 1702-09.
12. Means RT Jr, Dessypris EN, Krantz SB. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol. 1992; 150: 59-64.
13. Chuncharunee S, Carter CD, Studtmann KE, Caro J, Coffey RJ, Dessypris EN. Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumour necrosis factor in vivo. Br J Haematol. 1993; 84: 374-80.
14. Fandrey J, Frede S, Jelkmann W. Inhibition of erythropoietin gene expression in vivo by cytokines. Blood. 1994; 84(Suppl.1): 131a(abst)
15. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992; 79: 1987-94.
16. Vannucchi AM, Grossi A, Rafanelli D, Statello M, Cinotti S, Rossi-Ferrini P. Inhibition of erythropoietin production in vitro by human interferon gamma. Br J Haematol. 1994; 87: 18-23.
17. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci. 1992; 50: 301-8.
18. DeGowin RL, Gibson DP. Erythropoietin and the anemia of mice bearing extramedullary tumor. J Lab Clin Med. 1979; 94: 303-11.
19. Dainiak N, Kulkarni V, Howard D, Kalmanti M, Dewey MC, Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy. Cancer. 1983; 51: 1101-06.
20. Wang CQ, Udupa KB, Xiao H, Lipschitz DA. Evidence suggesting a negative regulatory role for macrophages in murine erythropoiesis in vivo. Exp Hematol. 1994; 22: 370-6.
21. Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood. 1991; 78: 2564-67.
22. Means RT Jr, Krantz SB, Luna J, Marsters SA, Ashkenazi A. Inhibition of murine erythroid colony formation in vitro by interferon gamma and correction by interferon receptor immunoadhesin. Blood. 1994; 83: 911-5.
23. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P. In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood. 1989; 73: 678-83.
24. Furmanski P, Johnson CS. Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor. Blood. 1990; 75: 2328-34.
25. de Haan G, Dontje B, Loeffler M, Nijhof W. Microenvironmentally dependent effects on murine haematopoiesis by a prolonged interleukin-1 treatment. Br J Haematol. 1993; 85: 15-9.
26. Johnson CS, Cook CA, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO). Exp Hematol. 1990; 18: 109-13.
27. Roodman GD, Johnson RA, Clibon U. Tumor necrosis factor alpha and the anemia of chronic disease: effects of chronic exposure to TNF on erythropoiesis in vivo. Adv Exp Med Biol. 1989; 271: 185-96.
28. Ward HP, Kurnick JE, Pisarczyk MJ. Serum level of erythropoietin in anemias associated with chronic infection, malignancy, and primary hematopoietic disease. J Clin Invest. 1971; 50: 332-5.
29. Zarrabi MH, Lysik R, DiStefano J, Zucker S. The anaemia of chronic disorders: studies of iron reutilization in the anaemia of experimental malignancy and chronic inflammation. Br J Haematol. 1977; 35: 647-58.
30. Zucker S, Friedman S, Lysik RM. Bone marrow erythropoiesis in the anemia of infection, inflammation, and malignancy. J Clin Invest. 1974; 53: 1132-38.
31. Lockner D. Iron absorption and serum erythropoietin concentration in patients with cancer of the uterine cervix. Acta Med Scand. 1966; 180: 651-5.
32. Schreuder WO, Ting WC, Smith S, Jacobs A. Testosterone, erythropoietin and anaemia in patients with disseminated bronchial cancer. Br J Haematol. 1984; 57: 521-6.
33. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990; 322: 1689-92.
34. Case DC Jr, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993; 85: 801-6.
35. Smith DH, Goldwasser E, Yokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer. 1991; 68: 1101-05.
36. Greendyke RM, Sharma K, Gifford FR. Serum levels of erythropoietin and selected other cytokines in patients with anemia of chronic disease. Am J Clin Pathol. 1994; 101: 338-41.
37. Ponchio L, Beguin Y, Farina G et al. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Haematologica. 1992; 77: 494-501.
38. Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med. 1987; 109: 429-33.
39. Urabe A, Mitani K, Yoshinaga K, et al. Serum erythropoietin titers in hematological malignancies and related diseases. Int J Cell Cloning. 1992; 10: 333-7.
40. Barosi G, Liberato LN, Guarnone R. Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1993; 83: 365-9.
41. Jansen JH, Wientjens GJ, Fibbe WE, et al. Serum monocyte colony-stimulating factor, erythropoietin and interleukin-6 in relation to pancytopenia in hairy cell leukemia. Leukemia. 1992; 6: 735-7.
42. Pohl C, Schobert I, Moter A, et al. Serum erythropoietin levels in patients with Hodgkin's lymphoma at the time of diagnosis. Ann Oncol. 1992; 3: 172-3.
43. Hellebostad M, Marstrander J, Slrdahl SH, Cotes PM, Refsum HE. Serum immunoreactive erythropoietin in children with acute leukaemia at various stages of disease and the effects of treatment. Eur J Haematol. 1990; 44: 159-64.
44. Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol. 1992; 82: 648-53.
45. Ariad S, Clifford D, Penfold G, MacPhail AP, Bezwoda WR. Erythropoietin response in anaemic patients with multiple myeloma and other lymphoid malignancies infiltrating the bone marrow. Eur J Haematol. 1992; 49: 59-62.
46. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 1992; 6: 1268-72.
47. Jacobs A, Janowska-Wieczorek A, Caro J, Bowen DT, Lewis T. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol. 1989; 73: 36-9.
48. Bowen DT, Culligan D, Beguin Y, Kendall R, Willis N. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters. Leukemia. 1994; 8: 151-5.
49. Fisher JW, Roh BL. Influence of alkylating agents on kidney erythropoietin production. Cancer Res. 1964; 24: 983-8.
50. Magid E, Hansen P. The erythropoietin content of plasma from sheep treated with nitrogen mustard. Scand J Clin Lab Invest. 1966; 18: 347-52.
51. Barcelo AC, Bozzini CE. Erythropoietin formation during hypoxia in mice with impaired responsiveness to erythropoietin induced by irradiation or 5-fluorouracil injection. Experientia. 1982; 38: 504-5.
52. Host H, Skjaelaaen P. Comparative effects of cyclophosphamide and total body irradiation on erythropoietin production in rats. Scand J Haematol. 1966; 3: 154-7.
53. Wolff M, Jelkmann W. Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures. Ann Hematol. 1993; 66: 27-31.
54. Cerruti A, Castello G, Balleari E, Bogliolo G, Lerza R, Pannacciuli I. Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin. Exp Hematol. 1994; 22: 1261-63.
55. Piroso E, Erslev AJ, Caro J. Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hematol. 1989; 32: 248-54.
56. Birgegard G, Wide L, Simonsson B. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol 1989; 72: 462-6.
57. Beguin Y, Clemons GK, Oris R, Fillet G. Circulating erythropoietin levels after bone marrow transplantation: Inappropriate response to anemia in allogeneic transplants. Blood. 1991; 77: 868-73.
58. Gebbia V, Valenza R, Rausa L. The in vitro effect of recombinant erythropoietin on cisdiamminodichloroplatinum-induced inhibition of murine erythroid stem cells. Anticancer Res. 1990; 10: 1779-82.
59. Nikkels PGJ, de Jong JP, Ploemacher RE. Effects of cic-diamminedichloroplatinum (II) upon haemopoietic progenitors and the haemopoietic microenvironment in mice. Br J Haematol. 1988; 68: 3-9.
60. Rothman SA, Paul P, Weick JK, McIntyre WR, Fantelli F. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning. 1985; 3: 415-23.
61. Matsumoto T, Endoh K, Kamisango K, et al. Effect of recombinant human erythropoietin on anticancer drug-induced anaemia. Br J Haematol. 1990; 75: 463-8.
62. Lechner W, Artner Dworzak E, Solder E et al. Influence on erythropoietin levels of treatment with cisplatinum-endoxan. Arch Gynecol Obstet. 1992; 252: 49-53.
63. Saijo Y, Nakai Y, Saito J et al. Changes in serum erythropoietin levels during chemotherapy for lung cancer. Chemotherapy. 1992; 38: 281-5.
64. Hasegawa I, Tanaka K. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecol Oncol. 1992; 46: 65-8.
65. Henry DH. Changing patterns of care in the management of anemia. Semin Oncol. 1992; 19: 3-7.
66. Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med. 1992; 116: 393-402.
67. Luban NLC. Transfusion medicine advances: a safer blood supply. Curr Opin Pediatr. 1991; 3: 105-12.
68. Williamson L. Homologous blood transfusions: the risks and alternatives. Br J Haematol. 1994; 88: 451-8.
69. Bordin JO, Blajchman MA. Immunosuppressive effects of allogeneic blood transfusions: implications for the patient with a malignancy. Hematol Oncol Clin North Am. 1995; 9: 205-18.
70. Blumberg N, Triulzi DJ, Heal JM. Transfusion-induced immunomodulation and its clinical consequences. Transfus Med Rev. 1990; 4: 24-35.
71. Vamvakas E, Moore SB. Perioperative blood transfusion and colorectal cancer recurrence: a qualitative statistical overview and meta-analysis. Transfusion. 1993; 33: 754-65.
72. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg. 1993; 80: 427-32.
73. Spivak JL. Recombinant human erythropoietin and its role in transfusion medicine. Transfusion. 1994; 34: 1-4.
74. Helm RE, Gold JP, Rosengart TK, Zelano JA, Isom OW, Krieger KH. Erythropoietin in cardiac surgery. J Card Surg. 1993; 8: 579-606.
75. Oster W, Herrmann F, Gamm H et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol. 1990; 8: 956-62.
76. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma, N Engl J Med. 1990; 322: 1693-99.
77. Cazzola M, Ponchio L, Beguin Y et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood. 1992; 79: 29-37.
78. Miller CB, Platanias LC, Mills SR, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst. 1992; 84: 98-103.
79. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol. 1994; 12: 1058-62.
80. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991; 9: 2021-26.
81. Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol. 1993; 4: 161-7.
82. Abels RJ. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol. 1992; 19: 29-35.
83. Henry DH. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer. Semin Hematol. 1993; 30(Suppl.6): 12-6.
84. Beguin Y, Loo M, R'Zik S et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood. 1993; 82: 2010-16.
85. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg L, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994; 84: 1056-63.
86. Abels RI, Henry DH. Predicting response to recombinant human erythropoietin. Ann Intern Med. 1993; 119: 91-2.
87. Beguin Y, Clemons G, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood. 1993; 81: 1067-76.
88. Naets JP, Wittek M. Effect of erythroid hypoplasia on utilization of erythropoietin. Nature. 1965; 206: 726-7.
89. Piroso E, Erslev AJ, Flaharty KK, Caro J. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol. 1991; 36: 105-10.
90. Mittelman M, Lessin LS. Clinical application of human erythropoietin in myelodysplasia. Hematol Oncol Clin North Am. 1994; 8: 993-1009.
91. Stein RS. Clinical use of growth factors in the myelodysplastic syndromes. Am J Med Sci. 1994; 307: 360-7.
92. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995; 89: 67-71.
93. Cazzola M, Ponchio L. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Blood. 1992; 80: 841-3.
94. Runde V, Aul C, Ebert A, Grabenhorst U, Schneider W. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. Eur J Haematol. 1995; 54: 39-45.
95. Hansen PB, Johnsen HE, Hippe E, Hellstrom-Lindberg E, Ralfkiaer E. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. Am J Hematol. 1993; 44: 229-36.
96. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood. 1993; 82: 737-43.
97. Hellstrom-Lindberg E, Birgegard G, Carlsson M, et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma. 1993; 11: 221-8.
98. Rosti V, Pedrazzoli P, Ponchio L, et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica. 1993; 78: 208-12.
99. Berdel WE, Oberberg D, Reufi B, Thiel E. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol. 1991; 63: 5-8.
100. Tomonaga M, Jinnai I, Tagawa M, et al. Leukemic blast cell colony formation in semisolid culture with erythropoietin: a case report of acute poorly differentiated erythroid leukemia. Blood. 1987; 69: 546-52.
101. Mitjavila MT, Villeval JL, Cramer P, et al. Effects of granulocyte-macrophage colony-stimulating factor and erythropoietin on leukemic erythroid colony formation in human early erythroblastic leukemias. Blood. 1987; 70: 965-73.
102. Asano Y, Okamura S, Shibuya T, Harada M, Niho Y. Growth of clonogenic myeloblastic leukemic cells in the presence of human recombinant erythropoietin in addition to various human recombinant hematopoietic growth factors. Blood. 1988; 72: 1682-86.
103. Motoji T, Hoshino S, Ueda M, et al. Enhanced growth of clonogenic cells from acute myeloblastic leukaemia by erythropoietin. Br J Haematol. 1990; 75: 60-7.
104. Okuno Y, Takahashi T, Suzuki A, et al. Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun. 1990; 170: 1128-34.